- Home
- MIRM vs MGIC Comparison
MIRM vs MGIC Comparison
Compare MIRM & MGIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- MGIC
- Stock Information
- Founded
- MIRM 2018
- MGIC 1983
- Country
- MIRM United States
- MGIC Israel
- Employees
- MIRM N/A
- MGIC N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- MGIC Computer Software: Prepackaged Software
- Sector
- MIRM Health Care
- MGIC Technology
- Exchange
- MIRM Nasdaq
- MGIC Nasdaq
- Market Cap
- MIRM 1.9B
- MGIC 673.6M
- IPO Year
- MIRM 2019
- MGIC 1991
- Fundamental
- Price
- MIRM $44.27
- MGIC $14.31
- Analyst Decision
- MIRM Strong Buy
- MGIC Buy
- Analyst Count
- MIRM 10
- MGIC 2
- Target Price
- MIRM $60.80
- MGIC $16.00
- AVG Volume (30 Days)
- MIRM 425.9K
- MGIC 30.7K
- Earning Date
- MIRM 05-07-2025
- MGIC 05-19-2025
- Dividend Yield
- MIRM N/A
- MGIC 3.92%
- EPS Growth
- MIRM N/A
- MGIC N/A
- EPS
- MIRM N/A
- MGIC 0.75
- Revenue
- MIRM $379,251,000.00
- MGIC $552,520,000.00
- Revenue This Year
- MIRM $29.51
- MGIC $7.53
- Revenue Next Year
- MIRM $20.27
- MGIC $4.89
- P/E Ratio
- MIRM N/A
- MGIC $19.21
- Revenue Growth
- MIRM 69.31
- MGIC N/A
- 52 Week Low
- MIRM $23.83
- MGIC $9.51
- 52 Week High
- MIRM $54.23
- MGIC $14.48
- Technical
- Relative Strength Index (RSI)
- MIRM 56.45
- MGIC 61.13
- Support Level
- MIRM $40.00
- MGIC $13.64
- Resistance Level
- MIRM $47.43
- MGIC $14.48
- Average True Range (ATR)
- MIRM 2.07
- MGIC 0.26
- MACD
- MIRM 0.54
- MGIC 0.05
- Stochastic Oscillator
- MIRM 65.27
- MGIC 88.28
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About MGIC Magic Software Enterprises Ltd.
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. It generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel; Europe; Japan, and Other countries.